Wolfe Research Initiates Coverage of CG Oncology (CGON) with Peer Perform Recommendation
Fintel reports that on May 19, 2026, Wolfe Research initiated coverage of CG Oncology (NasdaqGS:CGON) with a Peer Perform recommendation.
Analyst Price Forecast Suggests 44.26% Upside
As of May 14, 2026, the average one-year price target for CG Oncology is $90.78/share. The forecasts range from a low of $75.75 to a high of $113.40. The average price target represents an increase of 44.26% from its latest reported closing price of $62.93 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for CG Oncology is 65MM, an increase of 1,174.36%. The projected annual non-GAAP EPS is -1.35.
What is the Fund Sentiment?
There are 240 funds or institutions reporting positions in CG Oncology. This is an decrease of 122 owner(s) or 33.70% in the last quarter. Average portfolio weight of all funds dedicated to CGON is 0.80%, an increase of 124.19%. Total shares owned by institutions increased in the last three months by 13.32% to 93,118K shares. 
The put/call ratio of CGON is 0.39, indicating a bullish outlook.
What are Other Shareholders Doing?
Rtw Investments holds 6,985K shares representing 7.92% ownership of the company. In its prior filing, the firm reported owning 2,012K shares , representing an increase of 71.19%. The firm increased its portfolio allocation in CGON by 462.11% over the last quarter.
T. Rowe Price Investment Management holds 6,720K shares representing 7.62% ownership of the company. In its prior filing, the firm reported owning 423K shares , representing an increase of 93.71%. The firm increased its portfolio allocation in CGON by 2,727.91% over the last quarter.
Decheng Capital holds 6,372K shares representing 7.22% ownership of the company. No change in the last quarter.
Wellington Management Group Llp holds 5,371K shares representing 6.09% ownership of the company. In its prior filing, the firm reported owning 6,000K shares , representing a decrease of 11.70%. The firm decreased its portfolio allocation in CGON by 77.94% over the last quarter.
TCG Crossover Management holds 3,670K shares representing 4.16% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.